{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:01:06Z","timestamp":1791298866819,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"am","delay-in-days":321,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["666003"],"award-info":[{"award-number":["666003"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016912","name":"MSD France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010463","name":"Institut Curie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010463","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ejca.2022.06.033","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:53:26Z","timestamp":1658192006000},"page":"105-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients"],"prefix":"10.1016","volume":"173","author":[{"given":"Mathilde","family":"Saint-Ghislain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-C\u00e9line","family":"Derrien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionnel","family":"Geoffrois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauris","family":"Gastaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-5135","authenticated-orcid":false,"given":"Thierry","family":"Lesimple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Negrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Penel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Emmanuel","family":"Kurtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Le Corre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dutriaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gardrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Barnhill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Matet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Cassoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Houy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8440-7785","authenticated-orcid":false,"given":"Toulsie","family":"Ramtohul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8378-8432","authenticated-orcid":false,"given":"Vincent","family":"Servois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Piperno-Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Henri","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5443-0802","authenticated-orcid":false,"given":"Manuel","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ejca.2022.06.033_bib1","article-title":"Germline MBD4 mutations and predisposition to uveal melanoma","volume":"1","author":"Derrien","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"10.1016\/j.ejca.2022.06.033_bib2","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1158\/1078-0432.CCR-19-1215","article-title":"Evolutionary routes in metastatic uveal melanomas depend on MBD4 alterations","volume":"25","author":"Rodrigues","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2022.06.033_bib3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","article-title":"Uveal melanoma","volume":"6","author":"Jager","year":"2020","journal-title":"Nat Rev Dis Prim"},{"issue":"13","key":"10.1016\/j.ejca.2022.06.033_bib4","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ejca.2022.06.033_bib5","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1002\/cncr.30258","article-title":"Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies","volume":"122","author":"Algazi","year":"2016","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2022.06.033_bib6","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00262-019-02352-6","article-title":"Pembrolizumab as first-line treatment for metastatic uveal melanoma","volume":"68","author":"Rossi","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2022.06.033_bib7","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/1908065","article-title":"Efficacy of immunotherapy in patients with metastatic mucosal or uveal melanoma","volume":"2018","author":"Mignard","year":"2018","journal-title":"J Oncol"},{"key":"10.1016\/j.ejca.2022.06.033_bib8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ctrv.2017.08.009","article-title":"Immune checkpoint blockade for unresectable or metastatic uveal melanoma: a systematic review","volume":"60","author":"Heppt","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.ejca.2022.06.033_bib9","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1038\/s41467-018-04322-5","article-title":"Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors","volume":"9","author":"Rodrigues","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ejca.2022.06.033_bib10","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1038\/s41467-019-12746-w","article-title":"Epigenetic modifiers DNMT3A and BCOR are recurrently mutated in CYLD cutaneous syndrome","volume":"10","author":"Davies","year":"2019","journal-title":"Nat Commun"},{"issue":"14","key":"10.1016\/j.ejca.2022.06.033_bib11","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1182\/blood-2018-05-852566","article-title":"MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML","volume":"132","author":"Sanders","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ejca.2022.06.033_bib12","first-page":"1133","article-title":"A germline MBD4 mutation was identified in a patient with colorectal oligopolyposis and early-onset cancer: a case report","volume":"42","author":"Tanakaya","year":"2019","journal-title":"Oncol Rep"},{"issue":"5\u20136","key":"10.1016\/j.ejca.2022.06.033_bib13","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00251-019-01108-x","article-title":"Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab","volume":"71","author":"Johansson","year":"2019","journal-title":"Immunogenetics"},{"issue":"2","key":"10.1016\/j.ejca.2022.06.033_bib14","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/annonc\/mds470","article-title":"Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy","volume":"24","author":"Penel","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.06.033_bib15","series-title":"A language and environment for statistical computing","year":"2015"},{"issue":"10","key":"10.1016\/j.ejca.2022.06.033_bib16","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1093\/annonc\/mdt278","article-title":"Correlation between overall survival and growth modulation index in pre-treated sarcoma patients: a study from the French Sarcoma Group","volume":"24","author":"Cousin","year":"2013","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2022.06.033_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112728","article-title":"Prognostic implications of MRI melanin quantification and cytogenetic abnormalities in liver metastases of uveal melanoma","volume":"13","author":"Ramtohul","year":"2021","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.ejca.2022.06.033_bib18","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nrc3816","article-title":"Hypermutation in human cancer genomes: footprints and mechanisms","volume":"14","author":"Roberts","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"6349","key":"10.1016\/j.ejca.2022.06.033_bib19","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"7793","key":"10.1016\/j.ejca.2022.06.033_bib20","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","article-title":"Pan-cancer analysis of whole genomes","volume":"578","year":"2020","journal-title":"Nature"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922003847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922003847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:34:41Z","timestamp":1762342481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922003847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":20,"alternative-id":["S0959804922003847"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.06.033","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.06.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}